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Tissue transglutaminase (tTG) has been implicated in the
pathogenesis of Parkinson disease (PD). However, exactly how
tTG modulates the structural and functional properties of
-synuclein (-syn) and contributes to the pathogenesis of PD
remains unknown. Using site-directed mutagenesis combined
with detailed biophysical and mass spectrometry analyses, we
sought to identify the exact residues involved in tTG-catalyzed
cross-linking of wild-type -syn and -syn mutants associated
with PD. To better understand the structural consequences of
each cross-linking reaction, we determined the effect of tTG-
catalyzed cross-linking on the oligomerization, fibrillization,
andmembrane binding of-syn in vitro. Our findings show that
tTG-catalyzed cross-linking of monomeric -syn involves mul-
tiple cross-links (specifically 2–3). We subjected tTG-catalyzed
cross-linked monomeric -syn composed of either wild-type or
Gln 3 Asn mutants to sequential proteolysis by multiple
enzymes and peptidemapping bymass spectrometry. Using this
approach, we identified the glutamine and lysine residues
involved in tTG-catalyzed intramolecular cross-linking of
-syn. These studies demonstrate for the first time that Gln79
and Gln109 serve as the primary tTG reactive sites. Mutating
both residues to asparagine abolishes tTG-catalyzed cross-link-
ing of -syn and tTG-induced inhibition of -syn fibrillization
in vitro. To further elucidate the sequence and structural basis
underlying these effects, we identified the lysine residues that
form isopeptide bonds with Gln79 and Gln109. This study pro-
vides mechanistic insight into the sequence and structural basis
of the inhibitory effects of tTG on -syn fibrillogenesis in vivo,
and it sheds light on the potential role of tTG cross-linking on
modulating the physiological and pathogenic properties of
-syn.
Parkinson disease (PD)2 is a progressive movement disorder
that is caused by the loss of dopaminergic neurons in the sub-
stantia nigra, the part of the brain responsible for controlling
movement. Clinically, PD is manifested in symptoms that
include tremors, rigidity, and difficulty in initiating movement
(bradykinesia). Pathologically, PD is characterized by the pres-
ence of intraneuronal, cytoplasmic inclusions known as Lewy
bodies (LB), which are composed primarily of the protein
“-synuclein” (-syn) (1) and are seen in the post-mortem
brains of PD patients with the sporadic or familial forms of the
disease (2).-Syn is a presynaptic protein of 140 residues with a
“natively” unfolded structure (3). Three missense point muta-
tions in -syn (A30P, E46K, and A53T) are associated with the
early-onset, dominant, inherited form of PD (4, 5). Moreover,
duplication or triplication of the -syn gene has been linked to
the familial form of PD, suggesting that an increase in -syn
expression is sufficient to cause PD. Together, these findings
suggest that-syn plays a central role in the pathogenesis of PD.
The molecular and cellular determinants that govern -syn
oligomerization and fibrillogenesis in vivo remain poorly
understood. In vitro aggregation studies have shown that the
mutations associated with PD (A30P, E46K, and A53T) accel-
erate -syn oligomerization, but only E46K and A53T -syn
show higher propensity to fibrillize than wild-type (WT) -syn
(6–8). This suggests that oligomerization, rather than fibrilli-
zation, is linked to early-onset familial PD (9). Our understand-
ing of the molecular composition and biochemical state of
-syn in LBs has provided important clues about protein-pro-
tein interactions and post-translational modifications that may
play a role in modulating oligomerization, fibrillogenesis, and
LB formation of the protein. In addition to ubiquitination (10),
phosphorylation (11, 12), nitration (13, 14), and C-terminal
truncation (15, 16), analysis of post-mortem brain tissues from
PD and Lewy bodies in dementia patients has confirmed the
colocalization of tissue transglutaminase (tTG)-catalyzed
cross-linked -synmonomers and highermolecular aggregates
in LBs within dopaminergic neurons (17, 18). Tissue transglu-
taminase catalyzes a calcium-dependent transamidating reac-
tion involving glutamine and lysine residues, which results in
the formation of a covalent cross-link via -(-glutamyl) lysine
bonds (Fig. 2F). To date, seven different isoforms of tTGs have
* This work was supported by the Swiss Federal Institute of Technology Lau-
sanne. The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to indi-
cate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. 1–7.
1 To whom correspondence should be addressed. Tel.: 41-21-69-39691-
31812; Fax: 41-21-693-96-65; E-mail: hilal.lashuel@epfl.ch.
2 The abbreviations used are: PD, Parkinson disease; tTG, tissue transglutami-
nase; WT, wild type; -syn, -synuclein; LB, Lewy body; ESI-MS, electro-
spray ionization-mass spectrometry; MALDI-TOF-MS, matrix-assisted laser
desorption/ionization-time-of-flight-mass spectrometry; TEM, transmis-
sion electronmicroscopy; POPG, 1-palmitoyl-2-oleoyl-sn-glycero-3-[phos-
pho-rac-(1-glycerol)]; PBS, phosphate-buffered saline; mo., monoisotopic;
NAC, non-amyloid component; ThT, thioflavin T.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 19, pp. 13128–13142, May 8, 2009
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
13128 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 19•MAY 8, 2009
 at EPFL Scientific Inform
ation and Libraries, on Novem
ber 10, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2009/05/06/M809067200.DC1.html
Supplemental Material can be found at:
been reported, of which only tTG2 seems to be expressed in the
human brain (19), whereas tTG1 and tTG3 are more abun-
dantly found in stratified squamous epithelia (20). Subsequent
immuno-histochemical, colocalization, and immunoprecipita-
tion studies have shown that the levels of tTG and cross-linked
-syn species are increased in the substantia nigra of PD brains
(17). These findings, combined with the known role of tTG in
cross-linking and stabilizing bimolecular assemblies, led to the
hypothesis that tTG plays an important role in the initiation
and propagation of -syn fibril formation and that it contrib-
utes to fibril stability in LBs. This hypothesis was initially sup-
ported by in vitro studies demonstrating that tTG catalyzes the
polymerization of the -syn-derived non-amyloid component
(NAC) peptide via intermolecular covalent cross-linking of res-
idues Gln79 and Lys80 (21) and by other studies suggesting that
tTG promotes the fibrillization of amyloidogenic proteins
implicated in the pathogenesis of other neurodegenerative dis-
eases such as Alzheimer disease, supranuclear palsy, Hunting-
ton disease, and other polyglutamine diseases (22–24). How-
ever, recent in vitro studies with full-length -syn have shown
that tTG catalyzes intramolecular cross-linking of monomeric
-syn and inhibits, rather than promotes, its fibrillization in
vitro (25, 26). The structural basis of this inhibitory effect and
the exact residues involved in tTG-mediated cross-linking of
-syn, as well as structural and functional consequences of
these modifications, remain poorly understood.
In this study, we have identified the primary glutamine and
lysine residues involved in tTG-catalyzed, intramolecularly
cross-linked monomeric -syn and investigated how cross-
linking these residues affects the oligomerization, fibrillization,
and membrane binding of -syn in vitro. Using single-site
mutagenesis andmass spectrometry applied to exhaustive pro-
teolytic digests of native and cross-linkedmonomeric-syn, we
identified Gln109 and Gln79 as the major tTG substrates. We
demonstrate that the altered electrophoretic mobility of the
intramolecularly cross-linked -syn in SDS-PAGE occurs as a
result of tTG-catalyzed cross-linking of Gln109 to lysine resi-
dues in theN terminus of-syn, which leads to the formation of
more compactmonomers. Consistentwith previous studies, we
show that intramolecularly cross-linked -syn forms off-path-
way oligomers that are distinct from those formed by the wild-
type protein and that do not convert to fibrils within the time
scale of our experiments (3–5 days). We also show that mem-
brane-bound -syn is a substrate of tTG and that intramolecu-
lar cross-linking does not interfere with the ability of mono-
meric -syn to adopt an -helical conformation upon binding
to synthetic membranes. These studies provide novel mecha-
nistic insight into the sequence and structural basis of events
that allow tTG to inhibit -syn fibrillogenesis, and they shed
light on the potential role of tTG-catalyzed cross-linking in
modulating the physiological and pathogenic properties of
-syn.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of -Syn Variants—
Site-directed mutagenesis of -syn was performed using PCR
with the QuikChangeTM site-directed mutagenesis kit (Strat-
agene, La Jolla, CA). A pT7 plasmid carrying the human wild-
type -syn gene was used as a template for mutagenesis. The
following mutations were introduced using appropriate
mutagenesis primers: Q79N, Q109N, K32R, K34R, K80R, and
K96R. The double mutants Q79N/Q109N and K32R/K34R
were obtained by introducing a second mutation into the gene
containing the corresponding first mutation. All constructs
were verified by sequencing. Wild-type -syn protein and its
mutants were expressed in Escherichia coli and purified as
described previously (12).
Cross-linking Reactions—Purified human WT or mutant
-syn (35 M) was cross-linked with 0.008 unit of guinea pig
tTG for 2 h at 37 °C. Reaction solutions contained 10 mM Tris
(pH 7.6), 150 mM NaCl, 10 mM dithiothreitol, 25 mM HEPES,
and 5 mM CaCl2, unless otherwise stated. The enzyme was
omitted from control samples because preliminary experi-
ments showed that the omission of CaCl2 or tTG from the reac-
tion produced similar results. Reactions were quenched by the
addition of excess EDTA (25 mM), and the degree of cross-
linking was assessed by native PAGE, SDS-PAGE, and mass
spectrometry. Prior to gel loading, aggregates of very high
molecular weight that formed during the incubation were
removed usingmicrocon filters with amolecular mass cutoff of
100 kDa (Millipore Corp., Bedford, MA). The retentate (high
molecular weight aggregates) and the flow-through solution
(monomeric -syn) were analyzed by 12% native PAGE or
SDS-PAGE.
Preparation of Large Unilamellar Vesicles, Small Unilamel-
lar Vesicles, and -Syn-Liposome Complexes—1-Palmitoyl-2-
oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] sodium salt
(POPG, Avanti Polar Lipids Inc., Pelham, AL) was purchased as
a chloroform solution, and the solvent was removed by evapo-
ration and lyophilization. The phospholipid was resuspended
to a final concentration of 10 mg/ml in a solution of 50 mM
HEPES (pH 7.5), 150 mM NaCl. To increase the efficiency of
large unilamellar vesicles formation, 10 cycles of freezing in dry
ice and thawing in a 37 °C water bath were carried out. Small
unilamellar vesicles were prepared by extrusion through a
100-nm polycarbonate membrane (Avestin, Mannheim, Ger-
many) according to the manufacturer’s instructions. The large
unilamellar vesicles and small unilamellar vesicle preparations
were stored at 4 °C and used within 5 days.
Cross-linking of Membrane-bound -Syn—For vesicle-bind-
ing assays, 10 M -syn was incubated with freshly prepared
POPG vesicles at a mass ratio of 1:18 in 20 mM sodium phos-
phate buffer (pH 7.5) containing 200MCaCl2. The CaCl2 con-
centration was optimized to prevent salt-induced dissociation
of membrane-bound -syn. The membrane binding of -syn
prior to and after the cross-linking reaction was analyzed by
monitoring the extent of -helical structure in membrane-
bound -syn using CD spectroscopy. Finally, the release of
-syn from the vesicles was triggered by the addition of 300mM
NaCl, and the samples were passed through filters with a
molecularmass cutoff of 100 kDa to separate the released-syn
from that contained in the vesicles. The filtratewas subjected to
SDS-PAGE and mass spectrometry (MS) analysis to assess the
cross-linking state of -syn.
Far-UVCircular Dichroism Spectroscopy—Far-UVCD spec-
trawere recorded at 25 °C in a Jasco J-715 spectropolarimeter at
-Syn Cross-linking by Transglutaminase
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protein concentrations of 10 or 30 M in degassed 20 mM
sodium phosphate buffer (pH 7.5) using 0.1-cm cuvettes. As
many as six spectra were collected for each sample to improve
the signal-to-noise ratio. All spectra were corrected for the
buffer base line.
Proteolytic Digestions—-Syn samples were digested in 10
mMTris (pH 7.6) and 150mMNaCl using chymotrypsin, Lys-C,
and/or Glu-C at a protein-to-enzyme ratio of 100:1 (w/w)
unless otherwise stated. Glu-C and chymotrypsin were
obtained from Bioconcept (Switzerland), and Lys-C was pur-
chased fromWako (Neuss, Germany). Digestions were carried
out for 2 h at 37 °C or overnight at room temperature. Reactions
were stopped by the addition of trifluoroacetic acid to a final
concentration of 2%. Samples were digestedwith chymotrypsin
or trypsin gold (Promega, Du¨bendorf, Switzerland) overnight,
unless otherwise stated. The digestion was stopped with 1 l of
10% trifluoroacetic acid, and samples were stored at 4 °C until
further use.
Infusion Electrospray Ionization-Mass Spectrometry—Sam-
ples were infused at a low flow rate (250 nl/min) through a
TriVersa NanoMate source (Advion BioSystems, Ithaca, NY),
and MS detection was performed with an LTQ ion trap
(Thermo Scientific, Wohlen, Switzerland). After proteolytic
digestion, 1.5–2 g of each sample was desalted and concen-
trated using C18 Stage Tips (Proxeon, Odense, Denmark) and
subsequently analyzed. Specific peptide sequence information
was generated by manual collision-induced dissociation frag-
mentation of the peaks of interest, and Ultra-Zoom single-ion
monitoring mode was used when high resolution acquisitions
were required. TheGPMAWtool (version 7.1, Lighthouse data,
Odense, Denmark) was used to generate a list of expected pep-
tides from the different enzymatic digestions, as well as to com-
pute their theoretical fragmentation patterns. The comparison
of experimentally measured fragmentation signatures against
theoretical ones was performed manually.
Matrix-assisted Laser Desorption/Ionization-Time-of-Flight-
Mass Spectrometry—Aliquots (2 l) of intact purified protein
samples were used for MALDI-TOF-MS measurements. Two
matrix solutions were prepared as follows: a saturated solution
of sinapinic acid in methanol (matrix solution 1) and a 14
mg/ml sinapinic acid solution in 0.1% trifluoroacetic acid/ace-
tonitrile (1:1, matrix solution 2). Depending on the sample and
the initial conditions, a dried droplet or a two-layer sample
preparation was selected for the molecular weight analysis. For
the two-layer preparation, a thin matrix layer was first gener-
ated on the target plate using matrix solution 1. The sample (1
l) weremixedwith 1l of sinapinic acid/matrix solution 2 and
then 0.5l of thismixturewas deposited on top of the thin layer
and allowed to air-dry. In the dried dropletmethod, themixture
of sample andmatrix was deposited directly on the target plate.
Samples were deposited twice and analyzed with an ABI 4800
MALDI-TOF/TOF instrument in linearmode (Applied Biosys-
tems, Rotkreuz, Switzerland). Typically, 2400 laser shots were
summed by random sampling of the surface to generate the
spectra thatwere calibrated externally using the [MH]peak
of insulin, ubiquitin, and cytochrome c, all of which were pre-
pared with the samematrix and deposited close to the samples.
Sample Preparation for Analysis of ProteinDigests—Digested
protein samples were desalted on C18 StageTips (Proxeon,
Odense, Denmark) and mixed 1:1 with either 2,5-dihydroxy-
benzoic acid (20 mg/ml in 1% picolinic acid/acetonitrile (1:1
v/v)) or -cyano-4-hydroxycinnamic acid (7 mg/ml in acetoni-
trile, 0.1% trifluoroacetic acid (1:1 v/v)). Typically, 0.5 l of this
mixture was deposited on the target plate and allowed to air-
dry. Samples were analyzed on anABI 4800MALDI-TOF/TOF
instrument in reflectron mode.
Native and SDS-PAGE and Immunoblotting—Gels were pre-
pared using standard Laemmli techniques. Gels were stained
with Simply Blue Safe Stain (Invitrogen). ForWestern blot anal-
ysis, the separated proteins were transferred to a nitrocellulose
membrane (Omnilab, Mettmenstetten, Switzerland). The
membrane was blocked for 1 h at room temperature under
constant rocking using Odyssey blocking buffer (Li-COR Bio-
sciences, Bad Homburg, Germany) and diluted 1:3 in phos-
phate-buffered saline (PBS). Membranes were incubated with
the following primary mouse monoclonal antibodies at 4 °C
with constant rocking overnight: mouse anti--syn (1:1000
dilution; epitope, residues 15–123 of -syn; BD Transduction
Laboratories), sc-211 (1:500 dilution; epitope, residues 21–125
of -syn; Santa Cruz Biotechnology), Zymed LB 509 (1:500
dilution; epitope, residues 115–122 of -syn; Zymed Laborato-
ries Inc.), H3C (1:500 dilution; epitope, amino acids 128–140 of
-syn), and 7071 (1:1000 dilution; epitope, N terminus of
-syn). H3C and 7071 antibodies were kindly provided by Dr.
Julia George (Urbana, IL) and Dr. Peter Lansbury (Cambridge,
MA), respectively. For detection of -glutamyl-lysine cross-
links, the mouse monoclonal IgM antibody 81D4 was used
(1:500 dilution; Covalab, Villeurbanne, France). Membranes
were washed four times with PBS-T (0.01% PBS containing
Tween 20), followed by incubation with goat anti-mouse IgM
conjugated to Alexa Fluor 680 or, in the case of the 81D4 anti-
body, to Alexa Fluor 800. Finally, membranes were washed four
times with PBS-T and three times with PBS and scanned in a
Li-COR scanner at a wavelength of 700 nm or, in the case of the
81D4 antibody, a wavelength of 800 nm.
Transmission ElectronMicroscopy (TEM)—Samples of-syn
(5–10 l) were deposited on Formvar-coated 200 mesh copper
grids (ElectronMicroscopy Sciences, Hatfield, PA). Grids were
washed with two drops of double-distilled H2O and stained
with 2 drops of freshly prepared 1% (w/v) uranyl acetate (Elec-
tronMicroscopy Sciences). Specimenswere viewed on a Philips
CIME 12 electron microscope, operated at 80 kV. Digitized
photographs were recorded with a slow scan CCD camera
(Gatan, model 679).
Aggregation Studies Using the Thioflavin T (ThT) Fluores-
cence Assay—A sample of -syn (35 M, 400 l) was incubated
at 37 °C with constant rotation. Samples for ThT readings and
TEM were taken after 24, 48, and 72 h of incubation, unless
stated otherwise. Fibril formation was monitored by ThT fluo-
rescence assay. Readings were carried out with both the protein
andThTconcentration of 5Meach in 100l of 50mMglycine-
NaOH (pH 8.5). ThT fluorescence measurements were
recorded on an “Analyst AD” spectrometer (Bucher Biotec,
Basel, Switzerland) at an excitation wavelength of 450 nm and
an emission wavelength of 485 nm. The relative fluorescence at
-Syn Cross-linking by Transglutaminase
13130 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 19•MAY 8, 2009
 at EPFL Scientific Inform
ation and Libraries, on Novem
ber 10, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
485 nm was used as a measure of the amount of fibrillar aggre-
gates formed in solution. All sampleswere analyzed in triplicate
and corrected for the fluorescence level of freshly solubilized
-syn. Values are expressed as the percentage increase in ThT
fluorescence of threemeasurements (means S.D.). Data were
plotted using Prism Graph Pad (version 4.0).
RESULTS
tTG Intramolecular Cross-linking Alters the Conformational
Properties of theC-terminalRegionof-Syn—PurifiedhumanWT
andmutant-syn (30M)were cross-linkedwith tTG (0.008unit)
for 2 h at 37 °C. Prior to gel loading, the cross-linking reaction
mixturewaspassed througha filterwithamolecularmasscutoff of
100 kDa to remove larger aggregates (retentate) that formed dur-
ing the incubation. The cross-linked monomeric species, which
elute through this filter, were then analyzed by 12% native PAGE.
Fig. 1A shows that the presence of tTG resulted in a significant
shift in the migration of monomeric -syn (lanes 4–6). Under
these conditions,weobserved90%cross-linkingofWT-synor
the PD-associated mutants A30P and A53T. The cross-linking
productsof-synaremonomeric andcontainonly intramolecular
cross-links. Although these observations have been highlighted in
previous studies (25,26), thestructuralbasisunderlying thealtered
electrophoretic mobility of cross-linked monomeric -syn has
remained a mystery. The CD spectra of native and intramolecu-
larly cross-linked monomeric -syn were virtually identical and
were consistent with a random coil structure (Fig. 8).We hypoth-
esized that the conformational changes induced by tTG-catalyzed
cross-linkingshouldaffect theabilityofantibodies torecognize the
monomer. To test this hypothesis, tTG cross-linked humanWT,
A30P, and A53T -syn samples were analyzed by Western blot-
ting using antibodies against various regions of -syn as follows:
N-terminal region (7071 and BD Biosciences (epitope residues
15–123)), C-terminal region (sc-211 (epitope residues 121–125)),
H3C region (epitope residues 128–140), and LB 509 region
(epitoperesidues115–122).Asexpected, all theN-andC-terminal
antibodies recognized the bands corresponding to native, non-
cross-linked WT and mutant -syn (Fig. 1A, lanes 1–3). The
intramolecularly cross-linked monomeric -syn was recognized
by antibodies against residues within the C-terminal region 121–
140, but not by antibodies specific for residues in the C-terminal
regionof115–122. Interestingly, the intramolecularly cross-linked
monomers were only weakly detected by antibodies against the
N-terminal region of -syn (Fig. 1A, lanes 4–6). These findings
suggest that tTG catalyzes the formation of intramolecular cross-
links involvingC-terminal andN-terminal residues inmonomeric
-syn. The monoclonal antibody 81D4, which reacts with N-
(-L-glutamyl)-L-lysine isopeptides, recognized full-length cross-
linked-syn but not the nativemonomeric protein (supplemental
Fig. 1).
To further probe the conformational differences between
native and intramolecularly cross-linkedmonomeric -syn, we
subjected both species to proteolysis by chymotrypsin. Proteo-
lytic digestion of 30 M native -syn (WT, A30P, or A53T) at a
protein/enzyme ratio of 100:1 produced a proteolytic fragment
FIGURE 1. tTG-mediated intramolecular cross-linking of -syn alters its conformation, electrophoretic mobility, and accessibility to antibodies
against epitopes in theN-terminal region.A,monomericWT andmutant-syn analyzed in the absence (lanes 1–3) andpresence of tTG (lanes 4–6), with the
latter showing significant changes in electrophoreticmobility. The lettersM andm are used to designate native and intramolecularly cross-linked-synuclein,
respectively. For immunoblots, full sequence recognition was achieved for native, non-cross-linked WT and mutant -syn, using N-terminal and C-terminal
monoclonal antibodies (lanes 1–3); in contrast, the N termini were not detected in cross-linked samples (lanes 5 and 6). a.a., amino acids. B, SDS-PAGE analysis
of chymotrypsin proteolysis of native (lanes 2–7) and cross-linked WT and mutant -syn (lanes 8–13). Digestion of cross-linked samples gave a pattern of
proteolytic fragments (lanes 11–13) thatwas different from that of native-syn (lanes 5–7).C, sequence ofWT-syn showing the preferred enzymatic cleavage
sites of chymotrypsin (red), Lys-C (green), and Glu-C (blue).
-Syn Cross-linking by Transglutaminase
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of 5 kDa, which corresponded to residues 40–94 (Fig. 1B,
lanes 5–7). The corresponding tTG cross-linked monomers
were partially resistant to chymotrypsin proteolysis (Fig. 1B,
lanes 11–13), as evidenced by the presence of multiple bands in
the range of 5–17 kDa. This result suggests significant confor-
mational differences between the native and cross-linked-syn
monomer.
tTG-mediated Intramolecular Cross-linking of -Syn Occurs
Predominantly at Two Sites—To understand the structural
basis for the change in electrophoretic mobility that occurs
when -syn becomes intramolecularly cross-linked, we
sought to determine the number of tTG-induced cross-links
and the reactive residues involved. tTG was incubated with
WT -syn or -syn mutants associated with PD (A30P,
A53T), and the extent of cross-linking was determined by
MALDI-TOF-MS (linear mode) and SDS-PAGE. Native
monomeric forms of WT, A30P, and A53T -syn have
molecular masses, respectively, of 14460.2, 14486.2, and
14490.2 Da. tTG-catalyzed formation of an isopeptide bond
between a glutamine and lysine residue (transamidation)
results in the loss of 17.024 Da (Fig. 2F). In the presence of
tTG, we observedmolecular masses corresponding tomono-
meric -syn species containing one, two, or three tTG cross-
links (Fig. 2, A–C). The -syn monomer with two tTG-in-
duced cross-links was consistently observed to be the
predominant species under all cross-linking conditions
tested so far in our laboratory. These results demonstrate
that tTG-induced cross-linking of monomeric -syn occurs
at multiple residues. To determine whether multiple
intramolecular cross-linking is required for inducing the
conformational changes and altering the electrophoretic
mobility of monomeric -syn, we monitored the kinetics of
cross-linking and the shift in the monomeric band by
MALDI-TOF-MS and SDS-PAGE, respectively. Intramolec-
ular cross-linking of A30P -syn is a rapid process that takes
place within only a few minutes and appears to be complete
with two cross-links after only 45 min (Fig. 2, D and E).
Within the first 5–15 min, the singly cross-linked monomer
was the predominant species, whereas the doubly cross-linked
species became the predominant species after 45 min.
Although the shift toward the doubly and triply cross-linked
species was accompanied by an increase in the fast migrating
monomeric -syn, this species was observed within the first 5
min of the reaction. Similar results were observed for WT and
A53T -syn (data not shown). These results suggest that a sin-
gle specific intramolecular cross-linking reaction is responsible
for the structural changes in monomeric -syn and that this
cross-link may preferentially precede other cross-links.
FIGURE 2. tTG-catalyzed cross-linking of -syn involves one to three intramolecular cross-links. A–C,MALDI-TOF/TOF analysis of native (O) and cross-
linked (- - -) -syn, showing that most tTG-catalyzed cross-linking products of WT or disease-associated mutant forms of -syn are intramolecularly linked
(predominant peak with two cross-links), and up to three intramolecular cross-links can occur (left shoulder). The abbreviations M and m/cl are used to
designate native and cross-linked -synuclein, respectively. D and E, kinetic analysis of -syn (A30P) cross-linking monitored by MALDI-TOF and SDS-PAGE.
F, schematic depiction of the tTG-catalyzed chemical reaction (isodipeptide formation) between glutamine and lysine residues.
-Syn Cross-linking by Transglutaminase
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Residues Gln79 and Gln109 Are the Major Sites of tTG-cata-
lyzed Cross-linking—To identify the residues involved in tTG-
catalyzed cross-linking of -syn, both native and cross-linked
A30P -synuclein (30 M) were subjected to chymotrypsin
digestion and analyzed by SDS-PAGE and MALDI-TOF-MS.
Two different peptide fragments, residues 40–94 and 95–125,
were found to contain a single intramolecular cross-link (Fig.
3A, upper spectrum). We consistently observed the appear-
ance of a large peptide fragment with a mass average of m/z
[6555.4  H], which was due to the tTG-catalyzed cross-
linking of the C-terminal fragment (residues 95–125) to the
N-terminal fragment (residues 9–39) of -syn (Fig. 3,A andC).
The appearance of the N-terminal
fragment of-syn (residues 9–39) is
not consistent with the enzymatic
specificity of chymotrypsin, which
should normally generate a frag-
ment including residues 5–39.
However, because control diges-
tions produced the same fragment,
we cannot rule out the possibility
that -syn is susceptible to frag-
mentation at residue Leu8.
Cross-linking at Residue Gln79—
The fragment 40–94 contains two
glutamine residues that may partic-
ipate in tTG-catalyzed cross-link-
ing, Gln62 and Gln79. Previous stud-
ies by Jensen et al. (21) have shown
that tTG-catalyzed cross-linking of
peptides corresponding to the NAC
region of -syn involves the forma-
tion of an intermolecular isopeptide
bond between residues Gln79 and
Lys80. To determine whether the
single cross-link within the 40–94
fragment corresponds to an isopep-
tide bond between residues Gln79
and Lys80, wemutated glutamine 79
to an asparagine (Q79N). TheQ79N
mutant was subjected to tTG-cata-
lyzed cross-linking and chymotryp-
sin digestion under the same condi-
tions as those used for A30P -syn.
Consistent with the previous find-
ing (21), we did not observe any
tTG-catalyzed cross-links in the
fragment comprising residues
40–94, suggesting that residue
Gln79 is the primary substrate of
tTG-catalyzed cross-linking within
this region (Fig. 3A). Similar results
were observed for WT and the
A53T mutant. The Q79N mutation
does not affect the formation of the
two other cross-linked fragments
reported for A30P -syn, namely
intramolecularly cross-linked resi-
dues 95–125 and intermolecularly cross-linked fragments
(9–39) (95–125).
Cross-linking at Residue Gln109—The C-terminal fragment
95–125 contains two glutamine residues, Gln99 andGln109, and
three lysine residues, Lys96, Lys97, and Lys102, that may be
involved in the apparent tTG-catalyzed cross-linking of this
fragment. To determine which of the glutamine residues is
involved in tTG cross-linking, we mutated residues Gln99
and Gln109 to asparagine or glutamic acid (Q99E, Q109E, and
Q109N) and subjected these mutants to tTG cross-linking and
mass spectrometry analysis. Unlike the wild-type protein (Fig.
2A), cross-linking of the Gln79 and Gln109 mutants (Q79E,
FIGURE 3.MALDI-TOF/TOF analysis of chymotrypsin-digested cross-linked Q79Nmutant -syn. Proteo-
lytic digestion of cross-linked A30P (A, upper spectrum) and cross-linked Q79N -syn (A, lower spectrum) yields
a large fragment with masses of averagem/z 6558.12 [M H] and 6534.47 [M H], respectively, which is
explained by a cross-link between fragments 9–39 and 95–125. The difference in mass observed with these
cross-linked fragments accounts for thepresenceof aproline residue inA30P-syn.B,proteolytic fragments of
-syn generated by chymotrypsin. C, silver-stained SDS-PAGE of chymotrypsin digests, showing a large frag-
ment (white arrow) that appears to be resistant to further digestion, which may account for the cross-linked
fragments involving residues 9–39 and 95–125.
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Q79N,Q109E, andQ109N) resulted in the formation of a singly
cross-linkedmonomeric-syn as the predominant species (Fig.
4A). Interestingly, the Q79E and Q79N mutants exhibited
faster migration after tTG cross-linking, whereas the mutation
of Gln109 to Asn or Glu inhibited the formation of the fast
migrating -syn monomer (Fig. 4A). A second minor species
with two cross-links was observed in the case of all four
mutants. Together, these results suggest that residues Gln79
and Gln109 are the predominant tTG cross-linking sites and
demonstrate that the altered conformation and electrophoretic
mobility of monomeric -syn is because of tTG-induced
intramolecular cross-linking involving residue Gln109. To test
this hypothesis, we generated a double mutant in which resi-
dues Gln79 and Gln109 were both mutated to asparagine
(Q79N/Q109N). The double mutant Q79N/Q109N did not
undergo any cross-linking by tTG, and it exhibited, after incu-
bation with tGT, an electrophoretic mobility in the SDS-PAGE
identical to that of native non-cross-linked -syn (Fig. 4B).
These results suggest that cross-linking at residues Gln79
and/or Gln109 is required for the formation of the third cross-
link observed in the case of WT -syn and in the disease-asso-
ciated mutants A30P and A53T. Interestingly, cross-linking of
the Q99E mutant resulted in a shift in electrophoretic mobility
and in the formation of intramolecularly cross-linked mono-
meric species with predominantly two tTG cross-links; these
results are identical to those obtained by cross-linking of WT
-syn and the A30P mutant. This rules out the possibility that
residue Gln99 contributes to the conformational changes that
alter the electrophoretic mobility of cross-linked -syn.
Intramolecular Cross-linking by tTG Results in Covalent
Association between the C-terminal and N-terminal Regions of
-Syn—The detection of a large peptide corresponding to the
cross-linking of two peptide fragments 9–39 and 95–125 (Fig.
3A) raises the possibility that residue Gln109 may be cross-
FIGURE 4.ResiduesGln79 andGln109 are theprimary substrates for tTG-mediated cross-links.A, SDS-PAGE andMALDI-TOF/TOF analysis of tTG-mediated
cross-linkingofnative (O) andcross-linked (- - -)mutantsof-synwith substitutions at theputative reactiveglutamine residues.B,mutating residuesGln79 and
Gln109 to asparagine in the double mutant Q79N/Q109N abolishes tTG-mediated cross-linking of -syn, as can be seen by the unchanged, singly, and doubly
charged masses of full-length protein (average m/z 14431.37 [M  H] and 7216.18 [M  2H]2). Inset, SDS-PAGE analysis of tTG-incubated Q79N/Q109N
double mutant and A30P -syn. No shift in migration is observed with this double mutant as compared with A30P -syn. The abbreviation cl denotes
cross-linked -syn.
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linked to lysine residues in the N-terminal region including
residues 9–39. This hypothesis is consistent with NMR struc-
tural studies of monomeric -syn that show long range inter-
actions between the negatively
charged C-terminal region and the
positively charged N-terminal
region of -syn (27, 28). To deter-
mine the reactive lysine residues, we
performed extensive proteolysis
with multiple enzymes and mass
spectrometry studies of the result-
ing fragments. The theoretical and
preferred sites of these enzymatic
cleavages in-syn are shown in sup-
plemental Fig. 2. In the case of the
(9–39)  (95–125) cross-linked
species, proteolysis by chymotryp-
sin followed by Lys-C digestion is
expected to generate a fragment
comprising the N-terminal residues
24–32 cross-linked to the C-termi-
nal fragment 103–125. Indeed,
ESI-MS analysis of peptide frag-
ments from WT, A30P, and A53T
-syn revealed a peak with amass of
monoisotopic (mo.) m/z 1191.92
[M 3H]3 for WT and A53T and
mo. m/z 1200.56 [M  3H]3 for
A30P -syn (Fig. 5A). MS/MS frag-
mentation of cross-linked peptides
turned out to be very complex,
because both peptides that were
cross-linked fragment spontane-
ously (29), further complicating the
de novo peptide sequencing. Never-
theless, a detailed comparison
revealed a match between the frag-
mentation pattern of the candidate
parent ion signal of m/z 1191.92
[M 3H]3 and the predicted frag-
ments of the 103–25 cross-linked
sequence, providing direct evidence
of tTG-catalyzed isopeptide forma-
tion between residues Gln109 and
Lys32 (Fig. 5B). To further confirm
the involvement of residue Lys32, we
performed the cross-linking reac-
tions using mutants in which amino
acids Lys32 and/or Lys34 were
mutated to arginine (K32R, K34R,
and K32R/K34R). An analysis of
these lysine mutants revealed that
the formation of this cross-link is
likely to depend more on the struc-
tural properties of the protein than
on the primary sequence, because
both the K32R and the K34R
mutants retained the ability to
cross-link with residue Gln109 and form the cross-linked pep-
tide containing the peptide fragments 24–34 and 103–125
(supplemental Fig. 3). This indicates that residue Lys34 consti-
FIGURE 5. tTG-mediated cross-linking of residuesGln109 to Lys32.A, ESI-MS analysis of the digestion products
obtained after subjecting cross-linkedWT, A30P, and A53T -syn to sequential proteolysis with chymotrypsin fol-
lowed by Lys-C. Lys-C fails to cleave at residue Lys32, suggesting that this residue is cross-linked to residue Gln109
(inset in A). The difference in mass observed with A30P -syn is because of the proline residue. B, ESI-MS collision-
induceddissociation fragmentationofA30P-synof theparental fragmentofm/z1191.92 [M2H]2, inwhichthe
CandNterminiarecross-linkedtogether. FragmentationofC-terminal residues103–125appearedmoreevidentas
compared with N-terminal residues of 24–34. Nevertheless, the smallest detectable fragment with a mass ofm/z
625.28 could be associated to the N-terminal residues 31–33 cross-linked to the C-terminal residues 106–109.
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tutes an alternative site where tTG can catalyze cross-link for-
mation. Interestingly, intramolecular cross-linking of the dou-
ble mutant K32R/K34R also resulted in the formation of a fast
migrating monomeric -syn species, suggesting that these
mutants alter the structure of the monomer in a way that facil-
itates the residue Gln109 cross-linking with other lysine resi-
dues in the N terminus (supplemental Fig. 7).
Residue Gln10 Is Also Cross-linked to Residue Lys96—C-ter-
minal chymotryptic digestion of A30P and Q79N (Fig. 3), but
notQ109N-syn (data not shown), yielded a fragment contain-
ing residues 95–125 and a single tTG-catalyzed cross-link.
Using exhaustive proteolysis by chymotrypsin and Lys-C on
Q79N -syn, followed by ESI-MS fragmentation, we were able
to narrow down the residues involved in the cross-link between
residues Gln109 and Lys96 (supplemental Fig. 4A). Exhaustive
proteolysis of cross-linked Q79N -syn resulted in a peptide
containing a mis-cleaved C-terminal fragment (residues
95–97) cross-linked to a peptide containing residues 103–125
(mo.) m/z 963.33 [M  3H]3. The involvement of residue
Lys96 in the cross-link was confirmed by mutating amino acid
Lys96 to arginine. Analysis of the peptide fragments obtained
after tTG-catalyzed cross-linking and proteolysis by chymo-
trypsin revealed the absence of the intramolecular cross-link in
the 95–125 fragment of K96R -syn (supplemental Fig. 4B).
tTG-catalyzed Cross-link in the -Syn NAC Region Involves
Residues Gln79 and Lys60—Although previous findings suggest
that tTG-catalyzed cross-linking of the NAC peptide (residues
65–95) involves residue Gln79, the lysine residue(s) that react
with residue Gln79 have remained unknown. To determine
which lysine residue(s) is involved, A30P and Q79E -syn pro-
teins were subjected to tTG-catalyzed cross-linking, followed
by exhaustive digestion with chymotrypsin and Glu-C. Given
that tTG cross-linking involving residue Gln79 occurs mainly
within the region 40–94, we focused on the chymotryptic frag-
ments generated from this peptide. Proteolysis with Glu-C was
expected to yield a proteolytic fragment comprising residues
Glu62–Glu83. However, MS analysis of exhaustive digests of
cross-linked A30P -syn samples showed a predominant spe-
cies with one missed cleavage at residue Glu61, resulting in a
fragment comprising residues Lys58–Glu83 with a mass of mo.
m/z 2597.40 [MH] (Fig. 6A). The theoretical monoisotopic
mass of this fragment is 2614.43 [MH], indicating that this
fragment retains a single tTG-catalyzed cross-link (Fig. 6A, top
left inset). Nevertheless, a small population of the same cross-
linked Lys58–Glu83 fragment with a monoisotopic mass ofm/z
2615.42 [M  H] was found, clearly indicating cleavage at
residue Glu61 by Glu-C (Fig. 6A, top right of inset). This latter
fragment was the result of cross-linking between the Lys58–
Glu61 tetrapeptide (mo. 504.29 Da) and the Gln62–Glu83 frag-
ment (mo. 2127.15 Da): (504.29 2127.15 Da) 17.024 Da
mo.m/z 2615.41 [MH]. These findings suggest that residue
Gln79 cross-links to residue Lys60 instead of residue Lys80. To
test this hypothesis, we carried out similar studies with the dou-
ble mutant Q79E/Q79N. Analysis of the cross-linked Q79E
-syn digests revealed the absence of any cross-links within the
Lys58–Glu83 fragment, despite the presence of residue Gln62
within this sequence, which could act as a tTG substrate (Fig.
6A and below). To rule out the possibility that residue Lys80 is
involved in this cross-link, we mapped the lysine residues
involved in tTG-catalyzed cross-linking of residue Gln79 in the
Q109E mutant. We chose this mutant to allow examination of
intramolecular cross-linking within the N-terminal region in
the absence of conformational changes induced by cross-links
involving the C terminus. ESI-MS analysis of cross-linked
Q109E -syn subjected to sequential proteolysis with chymo-
trypsin followed by Lys-C clearly resulted in cleavage at residue
Lys80 and generation of a cross-linked proteolytic fragment
(Fig. 6B) with amonoisotopicmass ofm/z 1070.56 [M 2H]2,
corresponding to residues Thr59–Lys80. Control Lys-C diges-
tions of native Q109E -syn did not result in the formation of
any proteolytic fragments with missed cleavage sites, further
indicating that the mis-cleavage at residue Lys60 in tTG-cross-
linked Q109E -syn is due only to a cross-link present at this
residue. To further confirm the involvement of residue Lys60 in
this cross-link, we mutated Lys80 to arginine. If our hypothesis
was correct, then the K80R mutation should not influence the
number of tTG-catalyzed cross-links in monomeric -syn, and
we should still see the 59–80 fragment containing a single tTG-
catalyzed cross-link. Indeed, no changes in intramolecular
cross-links were found in full-length K80R mutant -syn, and
MS analysis of chymotrypsin digests still showed the presence
of a cross-link on a peptide fragment corresponding to residues
40–94 (Fig. 6C). Therefore, our results rule out the possibility
that residue Lys80 serves as a substrate in forming an intramo-
lecular cross-link within the NAC region.
IntramolecularCross-linking of theC- andN-terminal Region
of -Syn Induces a Conformational State That Does Not Form
upon Intermolecular Cross-linking of -Syn-(1–102) and
-(103–140)—To determine whether the formation of the com-
pact monomeric structure, rather than simple cross-linking of
the C- and N-terminal regions, is responsible for the change in
electrophoretic mobility and tTG inhibition of -syn fibrilliza-
tion, we investigated the cross-linking of a truncated mutant of
-syn-(1–102), which lacks the C-terminal region containing
103–140. Incubation of truncated -syn-(1–102) with tTG
resulted in the formation of two intramolecular cross-links
(supplemental Fig. 5A) but did not lead to a shift in themobility
of -syn in SDS-PAGE (supplemental Fig. 5C, lanes 4 and 5).
We reasoned that if the interactions between the C- and N-ter-
minal regions of -syn facilitate tTG-catalyzed cross-linking of
Gln109 with N-terminal lysine residues, then coincubation of
-syn-(1–102) with a purified C-terminal fragment comprising
residues 103–140 in the presence of tTG should result in the
formation of an intermolecular cross-link. Indeed, coincuba-
tion of both fragments in the presence of tTG resulted in the
formation of an -syn species with a molecular mass and SDS-
PAGE mobility similar to those of full-length -syn (supple-
mental Fig. 5,B andC).Mass spectrometry analysis of the cross-
linking product revealed a new peak (supplemental Fig. 5B,
right inset), with the mass ofm/z 14428.9375 [MH], which
is consistent with a transamidation reaction between intramo-
lecularly cross-linked -syn-(1–102) (average m/z 10156.32
[M  H]) and a C-terminal fragment (average m/z 4289.43
[MH]). Intermolecular cross-linking of -syn-(1–102) and
-(103–140) resulted in the appearance of a new band with
mobility identical to that of the native-synmonomer, suggest-
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ing that changes in electrophoretic mobility require cross-link-
ing of the full-length -syn monomer and that such mobility
shifts reflect conformational changes induced by intramolecu-
lar cross-linking of the C- and N-terminal regions of -syn.
tTG-catalyzed Intramolecular Cross-linking of WT and
Mutant -Syn Inhibits -Syn Fibrillization in Vitro—Previous
studies by Konno et al. (25) and Segers-Nolten et al. (26) have
shown that tTG-catalyzed cross-linking blocks the fibrillization
of -syn. To determine whether the intramolecular cross-
linked monomeric species produced under our conditions are
similar to those reported previously, we investigated their abil-
ity to aggregate and form amyloid fibrils in vitro. Purified
monomeric humanWT-syn and the disease-associated-syn
mutants A53T and A30P were cross-linked as described above.
Following cross-linking, monomeric -syn was separated from
both tTG-catalyzed and intermolecularly cross-linked higher
molecular weight aggregates using filters with amolecularmass
cutoff of 100 kDa, as described under “Experimental Proce-
dures.” Triplicate samples (400 l) of native and cross-linked
monomeric WT and mutant -syn (35 M) were incubated at
37 °C with agitation, and fibril formation was monitored by
ThT fluorescence and TEM. Under these conditions, the
majority of native A53T -syn was converted to fibrils within
72 h (Fig. 7, top), whereas the ThT signal of the cross-linked
monomer remained at base line even after extended incubation.
Similar results were observed for both WT and A30P -syn
(data not shown). TEM of the samples after 72 h revealed pre-
dominantly fibrillar assemblies in the samples containing
native A53T -syn, whereas cross-linked A53T -syn failed to
undergo fibrillogenesis and instead formed predominantly
FIGURE 6. Residue Gln79 is cross-linked to residue Lys60 within the NAC region of-syn. A,MALDI-TOF/TOF (reflectronmode) analysis of cross-linked and
digested A30P and Q79E -syn. Sequential digestion of cross-linked A30P and Q79E -syn with chymotrypsin followed by Glu-C generates a fragment of
residues 58–83, with a failure to cleave at residue Glu61. Only fragments derived from A30P -syn appear to bear a cross-link within this region, whereas
fragments fromQ79E-syn no longer bear this cross-link. A small population of A30P-synwas completely digested byGlu-C, and in this case two fragments,
Lys58–Glu61 and Gln62–Glu83, were found to be cross-linked. B, ESI-MS analysis of cross-linked Q109E -syn followed by chymotrypsin and Lys-C digestion
reveals a fragment containing residues Thr59–Lys80 and an internal cross-link (inset). The incomplete cleavage at residue Lys60 suggests a possible site of
cross-linking. C, MALDI-TOF/TOF analysis (reflectron mode) of chymotrypsin-digested native K80R -syn (upper panel) and cross-linked K80R -syn (lower
panel) demonstrates that cross-linking within the proteolytic fragment comprising residues 40–94 is detected, providing further evidence that residue Lys60
serves as the primary reactive lysine residue in this particular cross-link.
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spherical aggregates (Fig. 7). To determine which cross-link is
responsible for blocking the ability of cross-linked -syn to
undergo fibrillogenesis, we investigated the ability of theQ79N,
Q109N, and Q79N/Q109N mutants to undergo fibrillogenesis
before and after cross-linking with tTG. tTG-catalyzed cross-
linking of Q79N andQ109N -syn reduces their ability to form
fibrils (Fig. 7). Spherical aggregates similar to those formed by
the WT protein were observed to be the predominant species.
However, mutating both residues toQ79N andQ109N blocked
tTG-induced cross-linking and inhibition of amyloid formation
(see TEM in Fig. 7, clQ79N/Q109N), suggesting that tTG-cata-
lyzed cross-linking of residues Gln79 and Gln109 is essential for
inhibiting the fibrillization of -syn. To further investigate the
structural properties of the oligomeric species formed by cross-
linked-synmonomers, we compared their structure and amy-
loidogenic properties by TEM and ThT. Following incubation
of monomeric -syn with tTG, oligomeric aggregates were
recovered and separated from monomers by passing through fil-
ters with a molecular mass cutoff of 100 kDa. Oligomeric species
formed by non-cross-linked WT -syn monomers showed sub-
stantial ability to bindThT,whereas oligomeric species formed by
tTG-catalyzed cross-linking of monomers showed minimal ThT
binding (supplemental Fig. 6). These results suggest that these
oligomers do not possess amyloid-like structure, a finding that
is consistent with their inability to convert to amyloid fibrils
(supplemental Fig. 6).
Cross-linked -Syn Binds toMembranes of Lipid Vesicles and
Undergoes a Random Coil to -Helix Transition—To deter-
mine whether the tTG-catalyzed cross-linking of monomeric
-syn influences its membrane binding, we investigated the
ability of cross-linked -syn to bind synthetic membranes by
CD and filtration assays. Cross-linked WT, A30P, or A53T
-syn (17 M) was incubated with POPG vesicles at a protein/
vesicle ratio of 1:7 for 2 h at room temperature to allow suffi-
cient time for membrane binding. In the presence of POPG
vesicles, the secondary structure of both native and cross-
linked -syn monomers shifted from random coil to -helices
(Fig. 8A). To determine the extent of membrane binding, we
separated the vesicle-bound -syn from the free -syn by ultra-
centrifugation and filtration of samples through a membrane
with amolecular mass cutoff of 100 kDa, and then the retentate
and flow-throughwas analyzed using SDS-PAGE. Fig. 8B (lanes
4 and 7) shows that both native and tTG cross-linked -syn
monomers bound completely to POPG vesicles. It should be
noted that 100% POPG containing vesicles are highly charged
and provide much more driving force for membrane interac-
FIGURE 7. tTG inhibition of-syn fibrillization ismediated by intramolecular cross-linking that involves residues Gln79 andGln109.Negatively stained
TEM images (scale bar, 0.2 m) and the corresponding ThT fluorescence of native and cross-linked A53T (upper panels) and Gln to Asn -syn mutants (Q79N,
Q109N, andQ79N/Q109N; lower panels) after 3–4 days of incubation under fibril-forming conditions. The ThT values are themean S.D. of three independent
measurements. cl, cross-linked.
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tion, which may not be the case for membranes with a physio-
logically relevant lipid composition.
To further probe the effect of tTG-catalyzed cross-linking on
themembrane binding properties of -syn, we sought to deter-
mine whether cross-linking membrane-bound monomeric
-syn disrupts its secondary structure and membrane binding.
Native and tTG cross-linked WT -syn and the glutamine
mutants (Q79N, Q109N, and Q79N/Q109N) were incubated
with vesicles, and membrane binding was monitored by CD.
Fig. 8,C andD, shows that the secondary structure of themem-
brane-bound form of all four proteins was unaffected by tTG-
catalyzed cross-linking. In the membrane-bound state, the
N-terminal region (1–85) of -syn adopts an -helical confor-
mation. However, it is likely that the membrane-bound struc-
ture of the cross-linked -syn may differ from that adopted
by the native state because of conformational strains induced by
the intramolecular cross-linking, particularly those involving
the C and N terminus of -syn.
To determinewhether intramolecular cross-linking of theC-
and N-terminal regions can still take place in the membrane-
bound monomeric form of -syn, tTG was incubated with
-syn bound to POPG vesicles and analyzed bymass spectrom-
etry. Dissociation of the membrane-bound -syn was achieved
by the addition of 300 mM NaCl, followed by passage through
filters with a molecular mass cutoff of 100 kDa to separate
released -syn from that contained in vesicles. We observed
that tTG-catalyzed cross-linking of membrane-bound -syn
occurs at only one position (Fig. 9), as evidenced by the change
inmonomericmass from averagem/z 14486.22H to 14469.88
H. This cross-link does not cause a shift in the migration of
-syn, consistent with NMR studies demonstrating that the C-
and N-terminal regions do not interact in the membrane-
bound state (30).
DISCUSSION
Tissue transglutaminase cross-links a wide range of protein
substrates in vitro, including several proteins implicated in the
pathogenesis of neurodegenerative diseases, such as A (31),
Tau (32, 33), and amyloid precursor protein (34), which are
linked to Alzheimer disease; -syn (21, 25, 26), which is linked
to Parkinson disease; and polyglutamine domains (35–37),
which are linked to Huntington disease and related polyglu-
tamine disorders. Interestingly, despite the presence of multi-
ple glutamine and lysine reactive sites in these proteins, tTG-
FIGURE8. tTGcross-linkingdoesnot interferewith thebindingof-syn to lipidvesiclemembranes.A,CDspectraof cross-linked (cl)-syn in thepresence
of vesicles. In the presence of POPG vesicles, cross-linked A30P -syn undergoes a change in secondary structure from random-coil (O) to -helices (- - -).
B, SDS-PAGEanalysis ofmembrane-boundnative (lane 5) and cross-linked (lane 6)monomeric-syn fromA after passage througha filterwith amolecularmass
cutoff of 100kDa. Both retentate (R) and flow-through (F)were separatedontoa12%SDS-PAGE (lanes 5–8;M,monomeric;m, cross-linkedmonomeric; L, lipids).
C and D, CD spectra of membrane-bound WT and Qmutant -syn before (C) and after (D) cross-linking.
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mediated cross-linking appears to be specific and involves a
small subset of glutamine and lysine residues (Ref. 38 and this
study), suggesting that tTG-catalyzed cross-linking of these
substrates depends on their primary sequence and/or their
conformation.
This study provides mechanistic insight into the sequence
and structural basis of events throughwhich tTG inhibits-syn
fibrillogenesis in vivo, and the study sheds light on the potential
role of tTG-catalyzed cross-linking in modulating the physio-
logical and pathogenic properties of-syn.Wehave shown that
tTG-catalyzed cross-linking ofmonomeric-syn involvesmul-
tiple (2 to 3) cross-links. By subjecting tTG cross-linked mono-
meric -syn to sequential proteolysis by multiple enzymes and
subsequent analysis of the digests by mass spectrometry, we
have succeeded in identifying the key glutamine and lysine res-
idues involved in tTG-catalyzed intramolecular cross-linking of
-syn. These studies show that the residues Gln79 and Gln109
serve as the primary sites of tTG-catalyzed cross-links. Mutat-
ing both residues to asparagines abolishes tTG-catalyzed cross-
linking of -syn and tTG-mediated inhibition of -syn fibrilli-
zation in vitro. To further understand the sequence and
structural basis of these effects, we sought to identify the lysine
residues that participate in the formation of isopeptide bonds
with residues Gln79 and Gln109.
Residue Gln109 participates in multiple cross-links involving
predominantly residue Lys32 and, to some extent, Lys96. Previ-
ous studies suggested that the change in electrophoretic mobil-
ity is associated with the formation of more compact -syn
monomers, but they did not provide further insight into the
structural basis underlying the conformational changes
induced by tTG. Using single-site mutagenesis to change each
of the putative glutamine (Gln79, Gln99, and Gln109) and lysine
(Lys32, Lys34, Lys60, Lys80, and Lys96) residues to asparagine and
arginine, we demonstrated that a single intramolecular cross-
link involving residues Gln109 and Lys32 is responsible for the
observed change in electrophoretic mobility of monomers
intramolecularly cross-linked using tTG. Cross-linking
between residueGln109 and theN-terminal lysine residue Lys32
is consistent with the long range interactions previously
reported between the C- and N-ter-
minal regions of -syn (27, 28). For-
mation of this cross-link occurs
independently of cross-links involv-
ing residue Gln79, and it appears to
facilitate the formation of a third
isopeptide between residues Gln99
and Lys96, resulting in further com-
paction of the cross-linked mono-
mer. Consistent with these conclu-
sions, mutation of residue Gln109 to
asparagine (Q109N) or to glutamic
acid (Q109E) abolished the change
in electrophoretic mobility ob-
served for WT, Q79N, and Q99N
-syn proteins cross-linked in the
presence of tTG. The rapid cross-
link formation within the first min-
utes of the reaction and the con-
comitant increase in the amount of protein migrating faster on
the gel suggest that cross-linking of the C and N termini pre-
cedes cross-linking of the NAC region. The conformational
changes caused by tTG intramolecular cross-linking of mono-
meric -syn explain our failure to detect cross-linked -syn
using antibodies against the N-terminal residues 15–120,
whereas C-terminal detection is readily achieved using anti-
bodies against residues distant from Gln109 (i.e. antibodies
Sc211-(121–125) andH3C-(128–140)). This observation high-
lights the potential impact of post-translational modifications
on the immunoreactivity of -syn and underscores the impor-
tance of using multiple antibodies against different regions in
-syn to analyze post-mortem tissues and biological samples.
The involvement of residue Gln79 in tTG-catalyzed cross-
linking was reported earlier by Jensen et al. (21), who showed
that tTG catalyzed intermolecular cross-linking and dimeriza-
tion of the NAC peptide. This is mediated by isopeptide forma-
tion between residue Gln79 of one subunit and residue Lys80 of
a neighboring subunit. The presence of Lys80 adjacent to Gln79
suggests that these two residues may be cross-linked by tTG.
This hypothesis was supported by a report by Ikura et al. (39)
showing that tTG-catalyzed cross-linking of synthetic A-(1–
28) results in the formation of an isopeptide bond between res-
idues Gln15 and Lys16 and a shift in the SDS-PAGE mobility of
A-(1–28). However, in this study, we ruled out the possibility
that residue Lys80 serves as a tTG substrate during intramolec-
ular cross-linking. Instead, we show that within the NAC region,
tTG-catalyzed cross-linking involves the formation of an isopep-
tide bondbetween residuesGln79 andLys60.Under the conditions
used here, intramolecular cross-linking appears to precede inter-
molecular cross-linkingofmonomeric-syn, although the latter is
favored at higher protein concentrations. Formation of cross-
linked -syn dimers was observed only after longer incubations
and/or at higher concentrations of protein and tTG.
Implications for the Mechanism of -Syn Aggregation and Its
Function in Health and Disease—Consistent with previous
reports (25, 26), we observed that intramolecular cross-linking
of -syn blocks its fibrillization and results in the accumulation
of spherical aggregates with structural morphologies and dye-
FIGURE 9. Limited tTG-mediated cross-linking of membrane-bound A30P -syn. Vesicle-bound -syn
(lane 2)wasdissociated frommembranesby increasing theNaCl solution concentration to300mM.Dissociated
-syn was subjected to filtration using filters with a molecular mass cutoff of 100 kDa, and the filtrate (lane 4)
was analyzed by MALDI-TOF-MS. MS analysis of vesicle-bound and cross-linked -syn shows limited (only 1)
cross-linking by tTG. This single cross-link does not induce the above observed shift in gel migration. The
abbreviations R and F denote retentate and flow-through, respectively.
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binding properties that are distinct from those of protofibrillar
aggregates formed by native, non-cross-linked -syn; these
results were observed for WT, A30P, and A53T proteins. The
non-fibrillar aggregates formed by intramolecularly cross-
linked -syn bind weakly to ThT and do not convert into amy-
loid fibrils even after extended incubation at 37 °C. The inhibi-
tion of -syn fibrillization may be explained by structural
distortions induced by the cross-linking of residues Gln79 to
Lys60 and/or of Gln109 to Lys32/ Lys34; both of these cross-links
are expected to alter the conformational properties of the NAC
region, which plays a crucial role in the initiation and propaga-
tion of -syn fibrillization. Interestingly, similar observations
have been reported for other unfolded and amyloid-forming
substrates of tTG, including Huntingtin, Tau, human Tau pro-
teins (4RD), and the N-terminal region of the yeast prion
Sup35 (SupNM). This means that tTG-mediated intramolecu-
lar cross-linking of these proteins inhibits their fibrillization
and results in the formation of soluble, non-amyloidogenic
aggregates (25, 40, 41). These observations are also consistent
with pathological findings showing the absence of tTG in Lewy
bodies and of polyglutamine inclusions containing elevated lev-
els of -(-glutamyl)-lysine cross-links, suggesting that the
tTG-catalyzed formation of intra- and/or intermolecular cross-
linked species occurs in the cytosol, and these species subse-
quently aggregate or become sequestered into inclusion bodies
(18, 42, 43).
Our studies do not address the functional consequences of
tTG cross-linking of -syn in vivo. However, the results pre-
sented here, in combination with published data, point to a
mechanistic model that can be tested in vivo and in cellular
models of synucleinopathies. Fig. 10 presents a schematic
depiction summarizing our current understanding of -syn
aggregation and membrane binding
and how cross-linking may affect
these processes. -Syn exists in the
cytosol in a disordered conforma-
tion and undergoes a reversible shift
from random coil to -helix upon
binding to membranes. Increased
expression, post-translational mod-
ifications (truncations), and/or oxi-
dative stress can trigger -syn oli-
gomerization and fibril formation.
Protofibrillar -syn has been shown
to induce toxicity via several
mechanisms, including disruption
of membranes and the formation
of amyloid pores. tTG-induced
intramolecular cross-linking of
-syn blocks the formation of
fibrils without significantly inter-
fering with the interaction of
-syn with membranes. Although
intramolecularly cross-linked -syn
remains capable of forming high
molecular weight aggregates, these
aggregates appear to be off-pathway
or dead-end products. These find-
ings suggest that tTG may protect against -syn toxicity by
increasing its solubility and inhibiting its ability to form toxic
aggregates (i.e. protofibrils and fibrils). Therefore, the increased
levels of tTGmeasured in the cerebrospinal fluid (44), as well as
the presence of cross-linked -syn in post-mortem brain tissue
of PD patients (18) and during normal aging (45), may reflect
the activation of natural defense mechanisms to prevent amy-
loid formation or promote clearance of -syn aggregates. This
hypothesis assumes that intramolecular cross-linking of -syn
does not disrupt the normal function(s) of -syn and that the
aggregates formed by the cross-linked monomer are not toxic.
Given that, several protein-protein and protein-ligand interac-
tions and post-translational modifications of -syn have been
mapped to the C-terminal region (residues 110–140). Covalent
cross-linking of the C- and N-terminal regions is expected to
affect these interactions and the accessibility of key residues
that are modified post-translationally. Furthermore, the effect
of tTG-catalyzed intra- and intermolecular cross-linking of
-syn on the subcellular localization of the protein has not been
investigated. It is likely that only a fraction of -syn is cross-
linked by tTG, whichmay be sufficient tomaintain-syn below
the critical concentration required for oligomerization without
significantly affecting its physiological functions. Further stud-
ies to elucidate the molecular and functional consequences of
tTG-induced cross-linking of -syn in vivo are required before
the exploration of therapeutic strategies based on modulating
tTG levels or activity.
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FIGURE 10. Schematic depiction summarizing our current understanding of -syn aggregation and
membrane binding and how cross-linking may affect these processes. Further studies to elucidate the
molecular and functional consequences of tTG-induced cross-linking of -syn in vivo are required before the
exploration of therapeutic strategies based on modulating tTG levels or activity.
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